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(57) ABSTRACT 
Recombinant protein C characterized by a high percentage 
of active protein can be obtained in the milk of transgenic 
mammals that incorporate DNAs according to the present 
invention. Transgenic mammals of the present invention are 
produced by introducing into developing embryos DNA that 
encodes protein C, such that the DNA is stably incorporated 
in the DNA of germ line cells of the mature mammals and 
inherited in normal, mendelian fashion. 
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EXPRESSION OF HUMAN PROTEIN C IN 
MAMMARYTISSUE OF TRANSGENIC 
MAMMALS 
This application is a continuation of application Ser. No. 
07/638,995, filed Jan. 11, 1991, now abandoned. 
The present invention relates to the production of natural 
and modified forms of the human coagulation factor protein 
C. In particular, the invention relates to a transgenic animal 
containing, stably incorporated in its genomic DNA, an 
exogenous gene which is expressed specifically in mammary 
tissue, such that protein C is secreted into milk produced by 
the animal. 
BACKGROUND OF THE INVENTION 
Protein C is an important component of the coagulation 
system that has strong anticoagulant activity. In its active 
form it is a serine protease that proteolytically inactivates 
Factors V and VIII 
Human protein C (hPC) is a 62 kD, disulfide-linked 
heterodimer consisting of a 25 kD light chain and a 41 kD 
heavy chain which circulates as an inactive Zymogen in 
plasma. At the endothelial cell surface it is activated to 
activated protein C (APC) by limited thrombin proteolysis in 
the presence of thrombomodulin; cleavage of an Arg-Leu 
bond in the amino terminal portion of the heavy cain releases 
a 12 amino acid peptide. See generally Gardiner & Griffin in 
PROGRESS IN HEMATOLOGY, Vol. XIII at page 265-278 
(Brown, Grune and Stratton, Inc. 1983). 
Several regions of the molecule have important implica 
tions for function as an anticoagulant in the regulation of 
hemostasis. The amino terminal portion of the light chain 
contains the nine Y-carboxyglutamic acid (Gla) residues 
required for calcium-dependent membrane binding and 
functional activation. Another post-translational modifica 
tion is 3-hydroxylation of aspartic acid reside 71, possibly 
required for calcium-dependent membrane binding which is 
independent of the binding activity of the Gla regions. 
There are a variety of clinical situations for which protein 
C may prove beneficial. It may serve as replacement therapy 
in homozygous deficient infants suffering from purpura 
fulminans neonatalis. Other conditions include patients with 
a previous history of warfarin-induced skin necrosis who 
must have additional warfarin therapy, heparin-induced 
thrombocytopenia, septic shock for prevention of intravas 
cular coagulation and organ damage, and for fibrinolytic 
therapy, as protein C can protect tRA from plasma inhibitor 
proteins. Table 1 represents one estimate of the number of 
individual cases of several clinical syndromes which might 
be treated by purified protein C. Because there has not been 
sufficient material available from plasma for clinical trials 
until recently, these data are necessarily based on an incom 
plete assessment of the therapeutic potential for protein C. 
TABLE 1 
PARTIAL ESTMATE OF U.S. CLINICAL 
REQUIREMENTS FOR PROTEIN C 
AND ACTIVATED PROTEIN C 
Estimated 
Dose (mg) # Treatments Total U.S. 
Indication Per Treatment Per Year Req. (Kg) 
Septic Shock 5-50 120,000 0.6-6.0 
Thrombolytic 10-100 800,000 8-80 
Therapy** 
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TABLE 1-continued 
PARTIAL ESTIMATE OF U.S. CLINICAL 
REQUIREMENTS FOR PROTEIN C 
AND ACTIVATED PROTEIN C 
Estimated 
Dose (mg) i Treatments Total U.S. 
Indication Per Treatment Per Year Req. (Kg) 
Hip Replacement 10-100 200,000 2-20 
Homozygous 3 100 x 365* 0.10 
Deficient 
Heterozygous 50 1,000 0.05 
Deficient 
Total 10.8-106.2 
* 100 individuals in U.S. x 365 treatment/year 
*Refers to the use of APC, following thrombolytic therapy, to prevent the 
refornation of blood clots. 
The gene for human protein C has been cloned and 
sequenced, as has bovine protein C gene. See Forster et al., 
Proc. Nat'l Acad. Sci. USA 82:4673 (1985); U.S. Pat. No. 
4,775,624. It is synthesized as an inactive precursor that 
undergoes several proteolytic events during the processes of 
secretion and activation. First, a signal sequence as pro 
teolytically removed upon secretion. A second proteolytic 
event removes the dipeptide lys 156 arg157, producing the 
inactive zymogen, a two chain disulfide bridged protein, 
consisting of a light chain of 155 amino acids and a heavy 
chain of 262 amino acids. The zymogen is activated by a 
final proteolytic event that removes residues 158-169, yield 
ing active protein C, a serine protease with potent antico 
agulant activity. Beckmann et al., Nucleic Acids Res. 
13:5233 (1985). 
In addition to proteolytic processing, human protein C 
undergoes several post-translation modifications. Perhaps 
most salient among these modifications is the Y-carboxyla 
tion of the first nine glutamic acid residues in protein C, by 
a vitamin K dependent enzyme. DiScipio & Davie, Bio 
chemistry 18:899 (1979). Gamma-carboxylation is required 
for anticoagulant activity, and is associated with Ca'- 
dependent membrane binding. The anticoagulant activity of 
protein C varies directly with the extent of Y-carboxylation, 
and the highest levels of activity are achieved only when 
Y-carboxylation of the sixth and seventh glutamic acid 
residues is effected. Zhang & Castellino, Biochemistry 
29:10829 (1990). 
Protein C is also post-translationally modified by 3-hy 
droxylation of aspartic acid 71. Drakenberg et al., Proc. 
Nat'l Acad. Sci. USA 80: 1802 (1983). Beta-hydroxylation 
may be important to protein C activity. Although its function 
is not known it has been suggested that it may be involved in Y-carboxyglutamic acid independent Ca' binding, and it 
may be required for full anti-coagulant activity. 
Human protein C is also glycosylated. Kisiel, J. Clin. 
Invest. 64: 761 (1979). It contains four potential N-linked 
glycosylation sites, located at Asn97, Asn248, Asn313 and 
Asn329. The first three signals match the consensus Asn 
X-Ser/Thr glycosylation sequences, and are actively glyco 
sylated. There is an atypical glycosylation signal at ASn329, 
Asn-X-Cys-Ser. The Asn329 signal is glycosylated in 
bovine protein C, but it is not yet known if Asn329 is 
glycosylated in human protein C. Miletich et al., J. Biol. 
Chem. 265: 11397 (1990). The pattern and extent of glyco 
sylation can alter the physiological activity of protein C. 
Until recently, human protein C for experimental and 
therapeutic use was obtained exclusively from human 
plasma. Unfortunately, the quantity of protein that can be 
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obtained from human serum is limited. Furthermore, prod 
ucts derived from human serum pose difficulties of reliabil ity, purity and safety. 
The expression of therapeutic proteins by recombinant 
DNA technology is an attractive alternative to plasma pro 
duction of protein C, in that it eliminates the risk of potential 
contamination with blood-borne viruses and theoretically 
provides an unlimited supply of product. But the complexity 
of the post-translational modifications, as discussed above, 
has rendered problematic the production of commercially 
useable amounts of suitably active protein C by expression 
in a heterologous host. 
In fact, it has not been possible to produce vitamin 
K-dependent proteins like protein C at sufficiently high 
levels in an active form, despite efforts to do so using a 
variety of expression systems. See Grinnell et al. in Volume 
11 of ADVANCES IN APPLIED BIOTECHNOLOGY 
SERIES, Chapter 3 (Gulf Publishing Co.). In particular, any 
prospect for expressing protein C in mammary glands of a 
transgenic animal and secreting the protein into milk, see, 
e.g., U.S. Pat. No. 4,873,316 (1989), is clouded by the fact 
that protein C is normally synthesized in the liver. Even 
HepG2 cell lines derived from human liver produce aberrant 
forms of protein C. Marlar & Fair (1985). 
In this regard, it has been observed that a mouse mam 
mary epithelial cell line (C-127) transfected with a bovine 
papilloma virus (BPV) vector bearing the cDNA for human 
protein C expressed protein C that was only 30-40% active. 
Further analysis revealed that the protein C contained dimin 
ished levels of Y-carboxyglutamic acid and little, if any, 
B-hydroxyaspartic acid. Suttie et al., Thrombosis Res. 44: 
129 (1986). These experiments indicate that mouse mam 
mary epithelial cells cannot perform all of the post-transla 
tional modifications necessary for obtaining suitably active 
protein C, which in turn casts doubt on the likelihood of 
obtaining such protein C from the milk of a transgenic 
mammal. 
SUMMARY OF THE INVENTION 
It is therefore an object of the present invention to provide 
a transgenic animal which produces in its milk recombinant 
protein C that comprises a significantly higher percentage of 
active protein than has been achieved heretofore. 
It is another object of the present invention to provide a 
process for producing protein C in commercially useable 
amounts, by means of a transgenic mammal. 
In accomplishing the foregoing objects, there has been 
provided, in accordance with one aspect of the present 
invention, a transgenic mammal containing an exogenous 
DNA sequence stably integrated in its genome, wherein the 
exogenous DNA sequence comprises a promoter operably 
linked to a DNA sequence encoding a polypeptide having 
protein C activity and a signal peptide, wherein the promoter 
is specifically active in mammary cells, particularly mam 
mary epithelial cells, and the signal peptide is effective in 
directing the secretion of the protein C into the milk of the 
transgenic mammal. In a preferred embodiment, the pro 
moter is a whey acidic protein promoter. 
In accordance with another aspect of the present inven 
tion, there has been provided a process for the production of 
protein C, comprising the steps of (A) providing a transgenic 
mammal characterized by an exogenous DNA sequence 
stably integrated in its genome, wherein the exogenous DNA 
sequence comprises a promoter operably linked to a DNA 
sequence encoding a polypeptide having protein C activity 
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and a signal peptide, the promoter being specifically active 
in mammary cells and the signal peptide being effective in 
directing the secretion of the protein C into the milk of the 
transgenic mammal; (B) producing milk from the transgenic 
mammal; (C) collecting the milk; and (D) isolating the 
polypeptide from the milk. In one preferred embodiment, the 
transgenic mammal is mouse, rabbit, pig, sheep or goat. 
In accordance with still another aspect of the present 
invention, a process has been provided for producing trans 
genic animals, comprising the steps of (A) providing a 
mixture containing a genetic construct; (B) subjecting the 
mixture to anion-exchange high performance liquid chro 
matography to obtain purified genetic construct; and there 
after (C) microinjecting an aqueous buffer solution contain 
ing the purified genetic construct into an animal embryo. In 
a preferred embodiment, step (B) comprises applying the 
mixture to an anion-exchange high performance liquid chro 
matography column, eluting the genetic construct from the 
column, and then subjecting the genetic construct to a 
second anion-exchange high performance liquid chromatog 
raphy. 
Other objects, features and advantages of the present 
invention will become apparent from the following detailed 
description. It should be understood, however, that the 
detailed description and the specific examples, while indi 
cating preferred embodiments of the invention, are given by 
way of illustration only, since various changes and modifi 
cations within the spirit and scope of the invention will 
become apparent to those skilled in the art from this detailed description. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1 is a schematic diagram representing WAPpCI, a 
construct which contains cDNA encoding human protein C 
inserted into an intact murine whey acidic protein (WAP) 
gene at the unique Kpnl site. 
FIG. 2 is a schematic representation of polymerase chain 
reaction (PCR) primer pairs useful to detect WAP-protein C 
DNAs in transgenic animals. 
FIG. 3 is a graph that shows the results of an enzyme 
linked immunosorbent assay (ELISA) of human protein Cin 
milk obtained from a transgenic mouse. 
FIG. 4 is a graph that shows the results of an APTT assay 
to determine human protein Canticoagulant activity in whey 
obtained from a transgenic mouse. 
FIG.5 is a graph that shows the results of Ca'-dependent 
and Ca'-independent light chain capture ELISAs which 
demonstrate that the Y-carboxyglutamic acid in human pro 
tein C in whey from transgenic mouse Y52 is similar to that 
in protein C derived from human serum. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Notwithstanding past failures to express recombinant 
protein C with suitably high activity in several different 
expression systems, including transformed mammary cells, 
it has been discovered that recombinant protein C charac 
terized by a high percentage of active protein can be 
obtained in the milk of transgenic animals that incorporate 
DNAs according to the present invention. Transgenic ani 
mals of the present invention are produced by introducing 
into developing embryos DNA that encodes protein C, such 
that the DNA is stably incorporated in the DNA of germline 
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cells of the mature animal and inherited in normal, mende 
lian fashion. 
In accordance with the invention, DNAS can be intro 
duced into embryos by a variety of means to produce 
transgenic animals. For instance, totipotent or pluripotent 
stem cells can be transformed by microinjection, calcium 
phosphate mediated precipitation, liposome fusion, retrovi 
ral infection or by other means. The transformed cells can 
then be introduced into embryos and incorporated therein to 
form transgenic animals. In a preferred method, developing 
embryos can be infected with retroviral vectors and trans 
genic animals can be formed from the infected embryos. In 
the most preferred method, however, the DNAs of the 
invention are injected into embryos, preferably at the single 
cell stage, which are allowed to develop into mature trans 
genic animals. 
Suitable protein C-encoding DNA used for producing 
transgenic animals in this fashion can be obtained using 
human liver tissue as a source for cloning the hPC gene. The 
DNA coding for protein C can be fused, in proper reading 
frame, with appropriate regulatory signals, as described in 
greater detail below, to produce a genetic construct which is 
then amplified, for example, by propagation in a bacterial 
vector, according to conventional practice. 
The amplified construct is thereafter excised from the 
vector and purified for use in microinjection. The purifica 
tion is preferably accomplished by means of high perfor 
mance liquid chromatography (HPLC), which rids the con 
struct of contamination from the bacterial vector and from 
polysaccharides typically present when other techniques, 
such as conventional agarose electroelution, are used. The 
preferred HPLC method entails sorbing the construct onto 
an anion-exchange HPLC support and selectively eluting the 
construct from the support, preferably with an aqueous 
sodium chloride solution, thereby to eliminate contamina 
tion from the vector. (Elution may be effected by other 
means, such as a pH gradient.) Alternatively but less pref 
erably, the excised construct can be purified by ultracen 
trifugation through an aqueous Sucrose gradient. 
Since it is preferable that the construct have the minimum 
amount of impurities, more than one cycle of HPLC or other 
purification is advantageous. In particular, the use of HPLC 
purified DNA for microinjection, as described above, allows 
for remarkably high transformation frequencies, on the order 
of 20% or more in both mice and pigs. 
All lactating animals, that is, all mammals, are suitable for 
use according to the present invention. Preferred mammals 
include mice, rats, rabbits, pigs, sheep, goats and cows. 
More particularly, mice, pigs, sheep and cows are preferred. 
Most preferred at present are mice, pigs and sheep. 
DNA constructs useful in the present invention provide a 
DNA sequence encoding protein C operably linked to all the 
cis-acting signals necessary for mammary tissue specific 
expression of protein C, post-translational modification of 
protein C, secretion of protein C into milk, and full biologi 
cal activity of protein C. 
DNAs useful in the invention include genomic or comple 
mentary DNAs that encode naturally occurring protein C. In 
a preferred embodiment DNAs encoding human protein C 
are employed, including cDNA and genomic DNAs. DNAS 
encoding protein C from other species may also be used, 
such as the protein C encoded by rats, pigs, sheep, cows and 
chimpanzees. 
Modified protein C sequences also can be employed in the 
present invention. Useful modifications in this context 
include but are not limited to those that alter the post 
translational processing of protein C, that alter the size of 
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protein C, that fuse protein C or portions thereof to portions 
of another protein, or that alter the active site of protein C. 
Preferred modifications include those that provide an acti 
vated protein C and those that provide for activation of 
protein C in the absence of thrombomodulin. In a preferred 
embodiment, modified forms of human protein C are 
employed. 
Such modifications can be introduced into protein C by 
techniques well known to the art, such as the synthesis of 
modified genes by ligation of overlapping oligonucleotide, 
and by introducing mutations directly into cloned genes, as 
by oligonucleotide mediated mutagenesis, inter alia. 
The cis-acting regulatory regions useful in the invention 
include the promoter used to drive expression of the protein 
C gene. Promoters useful in the invention are active in 
mammary tissue. Particularly useful are promoters that are 
specifically active in mammary tissue, i.e., are more active 
in mammary tissue than in other tissues under physiological 
conditions where milk is synthesized. Most preferred are 
promoters that are both specific to and efficient in mammary 
tissue. By "efficient' it is meant that the promoters are strong 
promoters in mammary tissue that can support the synthesis 
of large amounts of protein for secretion into milk. 
Among such promoters, the casein, lactalbumin and lac 
toglobulin promoters are preferred, including, but not lim 
ited to the o-, 3- and Y-casein promoters and the o-lactal 
bumin and B-lactoglobulin promoters. Preferred among the 
promoters are those from rodent (murine and rat), pigs and 
sheep, especially the rat B-casein promoter and the sheep 
B-lactoglobulin promoter. The most preferred promoters are 
those that regulate a whey acidic protein (WAP) gene, and 
the most preferred WAP promoter is the murine WAP 
promoter. 
Also important to the invention are the signal sequences 
that direct secretion of protein into the milk of the transgenic 
animal. In this regard, both endogenous and heterologous 
signal sequences are useful in the invention. Generally, the 
signal peptides of proteins normally secreted into milk are 
useful in the invention. The signal sequences of proteins that 
occur in high concentration in milk are particularly pre 
ferred, such as the signal peptides of the caseins, lactalbu 
mins and lactoglobulins, including, but not limited to the 
signal peptides of the C-, 3- and Y-caseins and O-lactalbumin 
and 3-lactoglobulin. More particularly, the signal sequence 
of whey acidic protein is preferred, most particularly the 
signal sequence of the murine whey acidic protein. 
Also particularly preferred are the signal peptides of 
secreted coagulation factors. Especially preferred in this 
regard are the signal peptides of protein C, and t-PA. Most 
especially preferred is the secretion signal of human protein 
C. 
Among the sequences that regulate transcription that are 
useful in the invention, in addition to the promoter 
Sequences discussed above, are enhancers, splice signals, 
transcription termination signals and polyadenylation sites, 
among others. Particularly useful regulatory sequences 
increase the efficiency of mammary cell specific expression 
of protein C in transgenic animals. 
Especially useful in this regard are the other transcription 
regulatory sequences of genes expressed at high levels in 
mammary cells, such as the o-, 3- and Y-casein genes and the 
O-lactalbumin and B-lactoglobulin genes mentioned above. 
Preferred sources for regulatory sequences in this regard are 
rodents (mice and rats), pigs and sheep. 
Exemplary of preferred regulatory sequences are those 
associated with the rat B-casein gene and the sheep f-lac 
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toglobulin gene, respectively. The regulatory sequences 
most preferred for use in the present invention are those 
associated with whey acidic protein genes. Particularly 
preferred in this context are regulatory sequences of the 
murine whey acidic protein. 
Among the sequences that regulate translation, in addition 
to the signal sequences discussed above, are ribosome 
binding sites and sequences that augment the stability the 
protein C mRNA. Especially useful are the translation 
regulatory sequences of genes expressed at high levels in 
mammary cells. For instance, the regulatory sequences of 
the C-, 3- and Y-casein genes and the O-lactalbumin and f-lactoglobulin genes are preferred, especially those from 
rodents (mice and rats), pigs and sheep. Even more particu 
larly preferred are the regulatory sequences of rat B-casein 
and the sheep B-lactoglobulin genes. 
The most preferred translational regulatory sequences of 
the invention are those of the whey acidic protein and the 
protein C genes. And the most particularly preferred regu 
latory sequences are those of the murine whey acidic protein 
and human protein C, including human genomic protein C 
and human protein C cDNA constructs, and including 
human protein C cDNA constructs that contain intron 
Sequences. 
Especially useful in the present invention are sequences 
that advantageously modulate post-translational modifica 
tions of protein C, such that the protein C produced in the 
transgenic animals of the invention is active. In particular, 
the genomic sequences of the human protein C gene are 
preferred. 
Thus, in accordance with the present invention a DNA 
sequence that encodes protein C is operably linked to 
cis-acting regulatory sequences which allow for efficient 
expression of protein Cin milk. The resulting chimeric DNA 
is introduced into a mammalian embryo, where it integrates 
into the embryonic genome and becomes part of the heri 
table genetic endowment of all the cells, including the germ 
line cells, of the adult which develops from the embryo. The 
protein C which is expressed in the mammary tissue and 
secreted into the milk of a transgenic mammal obtained in 
this manner displays a surprisingly high percentage of active 
protein, as measured by enzymatic and coagulation-inhibi 
tion assays which are conventionally employed to detect 
protein C activity, such as ELISAs, chromogenic activity 
assays and coagulation inhibition assays. Levels of active 
protein on the order of 80% to 90% or more are character 
istic of the protein C expressed in accordance with the 
present invention. 
Obtaining milk from a transgenic animal within the 
present invention is accomplished by conventional means. 
McBurney et al., J. Lab. Clin. Med. 64: 485 (1964). The 
protein C contained in such milk can be purified by known 
means without unduly affecting activity. One suitable 
approach to purification in this regard is immunoaffinity 
chromatography. Alternatively, the expressed protein C can 
be isolated from the milk by other conventional means, for 
instance, by the method of Kisiel, J. Clin. Invest. 64: 761 (1979). In any event, it is preferred that protein C produced 
in milk pursuant to the present invention should be isolated 
as soon as possible after the milk is obtained from the 
transgenic mammal, thereby to mitigate any deleterious 
effect(s) on the stability of the protein. 
The present invention is further described by reference to 
the following, illustrative examples. 
EXAMPLE 1. DNAs useful for expressing protein C in 
transgenic animals 
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The entire murine WAP gene including 2.5 kb of 5' 
untranslated sequence and 3' untranslated regions was 
obtained from L. Hennighausen. See Campbell et al., 
Nucleic Acids Res. 12:8685 (1984). The human placental 
cDNA for human protein C was obtained from C. Shoe 
macker. 
Standard recombinant DNA techniques were employed to 
generate the vectors and expression constructs of the pre 
ferred embodiments, and for other manipulations of DNA, 
as set forth below. See Sambrook et al., MOLECULAR 
CLONING, A LABORATORY MANUAL, Vol. 1-3 (Cold 
Spring Harbor Press 1989). 
(1) WAPpC1 
A DNA construct called WAPpC1 was made, consisting 
of the entire murine WAP gene containing one copy of 
human protein C cDNA inserted at the unique Kpnl site, 24 
base pairs 3' of the transcriptional start site of the WAP gene 
(FIG. 1). This WAP-protein C construct was ligated into a 
bluescribe vector (Stratagene) to facilitate further manipu 
lation. 
(2) WAPpC2 
WAPpC2 is similar to WAPpC1, comprising the entire 
murine WAP gene and human protein C cDNA but differs 
from WAPpC1 in lacking artefactual 5' flanking sequences 
present in WAPpC1 as a result of cloning procedures used to 
make that construct. Specifically, 33 bp 5' to the protein C 
ATG and 118'A's' at the 3' end of the protein C cDNA were 
removed by PCR, and new Kpnl sites were added at the 5' 
and 3' ends. 
EXAMPLE 2. Preparation of DNAs for microinjection 
DNA for microinjection was prepared according to the 
procedures described below for DNA from WAPpC1. 
The 9 kb WAPpC1 fragment was removed from the vector 
with the restriction enzyme EcoRI. After digestion with 
EcoRI the solution containing the WAPpC1 DNA was 
brought to 10 mM magnesium, 20 mM EDTA and 0.1% SDS 
and then extracted with phenol/chloroform. DNA was pre 
cipitated from the aqueous layer with 2.5 volumes of ethanol 
in the presence of 0.3M sodium acetate at -20° C. overnight. 
After centrifugation, the pellet was washed with 70% etha 
nol, dried, and resuspended in sterile distilled water. 
DNA for microinjection was purified by HPLC. The 
digested DNA was precipitated with isopropanol and then 
dissolved in TE buffer at 0.3 pg/ml. Fragments were purified 
by HPLC using a Waters GEN FAX PAC HPLC column. 
The column was run isocratically using a buffer consisting 
of 25 mM Tris-HCl (pH 7.5), 1 mM sodium EDTA, and 
0.63M NaCl. This is the minimum NaCl concentration that 
will elute the large construct fragment and results in the best 
resolution from the smaller vector fragment which elutes just prior to the construct fragment. About 15ug of digested 
DNA was loaded on the column at a time. The construct 
fragment samples from all of the chromatographic runs were 
then pooled, reprecipitated, and run through the column a 
second time. Results reported below, for both pigs and mice, 
were generated using HPLC-purified DNA. 
DNA concentrations were determined by agarose gel 
electrophoresis by staining with ethidium bromide and com 
paring the fluorescent intensity of an aliquot of the DNA 
with the intensity of standards. Samples were then adjusted 
to 10 ug/ml and stored at -20° C., prior to microinjection. 
EXAMPLE 3. Transgenic animals 
(1) Mice 
Transgenic mice were produced essentially as described 
by Hogan et al., MANIPULATING THE MOUSE 
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EMBRYO (Cold Spring Harbor Press 1986). The proce 
dures employed are outlined below. 
Glass needles for micro-injection were prepared using a 
micropipet puller and microforge. Injections were per 
formed using a Nikon microscope having Hoffman Modu 
lation Contrast optics, with Narashigi micromanipulators 
and a pico-injector driven by N (Narashigi). 
Fertilized mouse embryos were surgically removed from 
the oviducts of superovulated female CD-1 mice and placed 
into M2 medium. Cumulus cells were removed from the 
embryos with hyaluronidase at 300 ug/ml. The embryos 
were then rinsed in new M2 medium, and transferred into 
M16 medium for storage at 37° C. prior to injection. 
After injecting the DNA solution into the male pro 
nucleus, embryos were implanted into avertin-anesthetized 
CD-1 recipient females made pseudo-pregnant by mating 
with vasectomized males. Embryos were allowed to come to 
term and the newborn mice were analyzed for the presence 
of the transgene as described below. 
(2) Pigs 
Embryos are recovered from the oviduct. They are placed 
into a 1.5 ml microfuge tube containing approximately 0.5 
ml embryo transfer media (phosphate buffered saline +10% 
fetal calf serum, Gibco BRL). These are then centrifuged for 
12 minutes at 16,000xg RCF (13,450 RPM) in a microcen 
trifuge (Allied Instruments, model 235C). Embryos are 
removed from the microfuge tube with a drawn and polished 
Pasteur pipette and placed into a 35 mm petri dish for 
examination. If the cytoplasm is still opaque with lipid such 
that pronuclei are not visible, the embryos are centrifuged 
again for 15 minutes. Embryos to be microinjected are 
placed into a microdrop of media (approximately 100 ul) in 
the center of the lid of a 100 mm petri dish. Silicone oil is 
used to cover the microdrop and fill the lid to prevent media 
from evaporating. The petri dish lid containing the embryos 
is set onto an inverted microscope (Carl Zeiss) equipped 
with both a heated stage and Hoffman Modulation Contrast 
optics (200Xfinal magnification). A finely drawn (Kopf Ver 
tical Pipette Puller, model 720) and polished (Narishige 
microforge, model MF-35) micropipette is used to stabilize 
the embryos while about 1-2 picoliters of HPLC-purified 
DNA solution containing approximately 200-500 copies of 
DNA construct is delivered into the male pronucleus with 
another finely drawn micropipette. Embryos surviving the 
microinjection process as judged by morphological obser 
vation are loaded into a polypropylene tube (2 mm ID) for 
transfer into the recipient pig. 
(3) Other animals 
Methods for microinjection of other animal species are 
similar to the methods set forth above. 
EXAMPLE 4. Assessment via PCR of WAP/hPC con 
structs in transgenic animals 
(1) Preparation of DNA form transgenic animals 
DNA can be prepared from tissue of a transgenic animal 
of any species by the method exemplified below for mice. 
A 5 mm piece of mouse tail was removed from young, 
potentially transgenic mice at weaning (3 weeks of age), 
minced, and treated with proteinase K and SDS at 37° C. 
overnight. The mixture was then incubated with DNase-free 
RNase at 37° C. for 1–2 hours. DNA was precipitated from 
the mixture with sodium acetate and ethanol at -20° C. 
overnight, collected by centrifugation, washed in 70% etha 
nol and dried. The dried DNA pellet was used directly for 
PCR. In some cases the mixture was extracted extensively 
with phenol/chloroform prior to ethanol precipitation. 
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(2) Oligonucleotide probes used in the PCR assay 
Oligonucleotide pairs were used to prime polymerase 
chain reactions that detected the presence of WAP-protein C 
constructs in the transgenic animals. These pairs and their 
extension products are shown schematically in FIG. 2 Oli 
gonucleotide pairs that bridge the region from the WAP 
sequences 5' of the Kpn site and the endogenous WAP 
sequences which naturally lie 3' of the Kpnl site also 
provided positive controls in mice. 
(3) PCR reaction conditions and product analysis 
PCR reactions were performed using an annealing tem 
perature of 58 C., a denaturation temperature of 94°C., and 
an extension temperature of 72 C., using 100 ng of oligo 
primers and 50 ng of (genomic) template DNA per reaction, 
and cycling through the temperatures 40 times using an 
automatic temperature cycler (M. J. Research). 
PCR reactions were analyzed by running 20% of the 
reaction products on agarose gels and identifying fragment 
sizes by comparison with marker DNA fragments. 
(4) Results of PCR analysis of transgenic animals 
PCR analysis of potentially transgenic mice and pigs 
which developed from embryos microinjected with 
WAPpC1 and WAPpC2 constructs are summarized in Table 
2. The results show that WAPpC constructs frequently 
integrated into the embryonic genomes of both mice and 
pigs. Furthermore, mendelian transmission was observed in 
5 of the 16 mice which were tested. 
TABLE 2 
Whey Acid Protein-Protein C Construct Integration Rates 
Animal iTested if Positive Integration Rate 
Mice 05 30 29% 
Pigs 23 5 22% 
Mendelian Transmission in Transgenic Mice 
5/16 Tested see 31% 
EXAMPLE 5. Preparation of milk and whey from trans 
genic animals 
(A) Mice: Lactating mice were milked an average of 3 
times per week. The mice were first separated from their 
young for approximately 5 hours. They were then anesthe 
tized with 0.4 ml avertin at 2.5% (I.M.), and 0.2 ml oxytocin 
was then administered at 2.5IU/ml (I.P.) to permit release of 
the milk. A milking device consisting of a vacuum pump (2.5 
psi) and syringe with an eppendorf tip was used to direct 
milk into an eppendorf tube. During collection, milk was 
placed on ice until all samples were obtained. 
To prepare whey, milk was diluted 1:1 with TS buffer 
(0.03M Tris pH 7.4; 0.06 NaCl) and centrifuged in a 
TLA-100 rotor in a Beckman TL-100 table top ultracentri 
fuge at 51,000 rpm (89,000xg) for 30 minutes at 40 C. After 
centrifugation the tubes were put on ice, and the whey was 
collected with an 18 gauge needle, leaving the casein pellet 
and upper cream layer in the tube. To remove solids or cream 
that co-transferred during the initial recovery, the whey 
obtained from the first centrifugation was subjected to a 
second spin at 12,000 rpm for 30 minutes at 4° C. in a 
TMA-4 rotor in a Tomy MTX-150 centrifuge. Following the 
second spin the tubes were place on ice and the whey was 
recovered as before. 
EXAMPLE 6. Determination by ELISA of protein C 
produced by transgenic mammals 
An ELISA was used to measure the amount of protein C 
protein produced by transgenic animals in their milk or 
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whey. Two monoclonal antibodies, 7D7B10 and 12A8, and 
a polyclonal antiserum were used in the ELISAs, and a 
variety of other protein C specific antibodies could be 
employed. The 7D7B10 monoclonal is specific for the NH 
terminus of the light chain of protein C. 12A8 is specific for 5 
the reactive site on the heavy chain of protein C. 
Microtiter plate wells were coated overnight at 4°C. with 
3 g/ml of monoclonal antibody in 50 pil of 0.1M sodium 
bicarbonate buffer, pH 8.3. The wells were washed once 
with TET buffer (0.01M Tris pH 7.5; 0.01M EDTA; 0.02% 
tween-20, pH 7.45) and then blocked with 1% BSA in PBS 
using 400 ul per well for 1 hour at 37° C. Plates were again 
washed with TET buffer (5X) followed by addition of 100 ul 
of sample whey or normal whey spiked with human protein 15 
C from plasma, to generate a standard curve. After washing 
5X with TET buffer, horse radish peroxidase (HRP)-conju 
gated to rabbit anti-hPC was diluted 1:1000 in 0.1% BSA/ 
TET and 100 ul was added per well and incubated for 2 
hours at room temperature, with shaking at 100 rpm. After 
again washing 5 times with TET buffer, 100 ul of orthophe 
nyldiamine (OPD), from a stock solution made by dissolv 
ing one tablet of OPD in 20 ml of 0.1M citrate-phosphate 
buffer (pH 5.0), were added to each well. After 10 minutes 
at room temperature the reaction was stopped with 1N 
sulfuric acid. The extent of the reaction was determined by 
measuring product absorption at 490 nm. 
The result of an ELISA analysis of the milk from one 
transgenic mouse (Mouse No. 5) is shown in FIG. 3. 
Standard curves were obtained for a monoclonal antibody, 
12AB, and a rabbit polyclonal antibody, titered against 
human protein C which was obtained by immunoaffinity 
chromatography over immobilized 7D7B10 antibody. The 
milk sample, taken from transgenic Mouse No. 5, contained 
approximately 200 ng/ml protein C. 35 
To assure proper protein C structure as judged by immu 
nocapture by two different monoclonal antibodies, as well as 
by a polyclonal mixture of antibodies, the samples for 
several different transgenic mice were screened by ELISAs. 
Table 2A shows essentially equivalent antigen levels, as judged by three different immunocaptures and detection by 
ELISA. The majority of mice produced by microinjection of 
WAPpC1 produced antigen levels in the 1-to-4-pg/ml range. 
O 
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TABLE 2A 45 
hPCANTIGEN ELISA (NG/ML) 
POLY. 
MOUSE MONOCLONAL MONOCLONAL CLONAL 
ID-DAY LC-CAPTURE HC-CAPTURE CAPTURE 50 
Y52-15 1320 3530 4100 
Y57-15 930 150 2880 
The concentration of human protein C in whey obtained 55 
from transgenic mice, as well as milk, was also determined 
in this manner, with equivalent results. 
Similar assays were routinely carried out to assay protein 
C in milk obtained from transgenic animals. Results 
obtained using the 7D7B10 antibody in light-chain capture 
ELISAs are compiled in Table 3, which summarizes the 
concentration of protein C in milk obtained from transgenic 
mice during the first four lactation periods. Dashes indicate 
that no test was done. All of the animals provided significant 
levels of protein C in their milk. Preliminary results also 65 
indicate that the second lactation period is sometimes supe 
rior to the other periods tested. 
60 
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TABLE 3 
hPC ELISA SCREENING (LIGHT CHAIN CAPTURE) 
PC-Ag (ug?ml) 
Day of Lactation 
MOUSEED 5-6 8-9 11-12 13-15 
Y68-L2 -- 1.05 - - 
Y51-L2 -- 1.08 --- 0.56 
Y51-L3 - 2.80 1.30 1.79 
Y52-L1 - 0.55 0.65 - 
Y52-L2 - 152 - 0.95 
Y57-L1 - - 0.52 1.35 
Y57-L2 147 - 0.98 r 
R03-L2 1.90 2.88 3.01 - 
R12-LI --- 0.60 - - 
R12-L2 - 2.98 2.48 2.40 
Human protein C in the milk obtained from other species 
can be measured by the same methods. Thus, protein C from 
human plasma spiked into pig milk was accurately detected 
via the above-described ELISA. 
EXAMPLE 7. Assay for protein C amidolytic activity 
using the chromogenic substrate S-2366 
The enzymatic activity of protein C in the milk of 
transgenic animals was measured directly using a chromoge 
nic assay essentially as described by Odegaard et al., Hae 
mostasis 17:109 (1989). In this assay microtiter plate wells 
were coated with the 7D7B10 monoclonal antibody (50 
ug/ml) in 50 pil of 0.1M bicarbonate buffer, pH 8.6 at 4°C. 
overnight. Plates were then rinsed with TET buffer (0.1M 
Tris; 0.03M EDTA; 0.05% tween-20) and blocked with 400 
ul/well 1% BSA in PBS and incubated at room temperature 
for 1 to 1.5 hours. After rinsing 3 times with TET buffer, 50 
ul of whey sample and 50 pil of 0.1M Tris pH 7.5, 0.03M 
EDTA was added per well and incubated at room tempera 
ture for 2 hours. Plates were washed 3 times in TET buffer. 
The captured human protein C was activated by adding 120 
ul of ProtacTM, a commercial reagent containing a snake 
venom enzyme (12 ml distilled water per vial), 30 ul TSP 
buffer and 0.1% BSA, pH 7.5, per well. After incubation for 
6-10 minutes at room temperature, 120 ul S-2366 (Kabi 
substrate) at 25 mg/10.8 ml Tris pH 7.8 was added to each 
well and the plates were incubated for 2-8 hours at room 
temperature, or several days at 4 C. The amount of protein 
C activity in each sample was determined by measuring 
formation of the reaction product by absorption at 405 mm. 
Results obtained using milk and whey from a transgenic 
mouse and the pooled milk and whey of several transgenic 
mice appear in Table 4, which shows the amount and the 
specific activity of protein C in the samples. Note that the 
samples were obtained either during the first lactation 
period, L1, or were obtained from a second and third 
lactation, L2 and L3. The specific activity of the human 
protein C obtained from transgenic mice determined in these 
assays, 205 units (U) per mg, is similar to that of human 
protein C of similar purity obtained from natural sources. (A 
"unit' is defined by pooling blood from many individuals 
and determining activity in 1 ml of the pooled blood.) 
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TABLE 4 
Protac TM-Specific Amidolytic Activity 
Upon S-2366 
Ulml ug Agiml Ulmg 
Reconstituted Whey 0.07 0.34 206 
Y52-L1 Pool: 
Y52-L. Milk Pool 0.23 1.12 
Transgenic Whey Pool** 112 0.55 205 
Transgenic Milk Pool** 0.43 2.0 
*Pooled milk from days 5-15. 
**L2 and L3 from mice Y5, Y52, Y57, R03, R12. 
EXAMPLE 8. Determination of protein C produced in 
transgenic mammals by activated partial thromboplastin 
clotting time assay 
The activity of protein C was also measured in a clotting 
time assay, the activated partial thromboplastin clotting time 
assay (APTT). In this assay, each well of a plastic Coag-a- 
mate tray received 90 ul of PC-deficient plasma plus 10 ul 
of an APC standard or unknown, diluted with Tris/saline/ 
BSA. The tray was then placed on an automated analyzer 
(APTT mode, 240 second activation). The run was started, 
which automatically performed the addition of 100 pil of 
APTT reagent and 100 ul of 0.025M CaCl. Data obtained 
using a standard APC preparation was fitted to the equation 
y-ax+b where y-clotting time and x=APC, which was then 
used to determine the amount of APC in a sample. 
The result of an APTT assay of whey pooled from 
transgenic mice is shown in FIG. 4. The standard curves in 
the figure correlate the activity determined by the APTT 
assay with the amount of active human protein C in mouse 
milk or mouse whey. The activity in the APTT assay of the 
whey sample obtained from the transgenic mouse corre 
sponded to a concentration of approximately 0.57 g/ml, 
interpolated from the standard curve for human protein C in 
whey. An ELISA (not shown) of the same whey sample 
detected approximately 0.60 g/ml of human protein C, as 
protein. Thus, within the normal range of error of these 
assays, human protein C produced in transgenic mice is as 
active as the control human protein C. 
EXAMPLE 9. Mapping of Calcium Dependent Con 
former by Metal-Dependent Immunoafinity 
Standard ELISAs were run in normal mouse milk whey 
with varying concentrations of hPC or hPC without Gla 
regions in the presence of 25 mM EDTA. After capture by 
7D7B10, an assay replicating that effected with 25 mM 
EDTA was treated with several washes of 25 mM CaCl2, and 
then was followed by the ELISA detection protocol 
described previously. While de-Gla protein remained bound 
to the capture antibody in the presence of CaCl2, the PC 
standard did not remain bound in the presence of added 
CaCl. It was observed that whey from the transgenic mouse 
Y57 behaved in a similar manner to the y-carboxylated 
native PC, suggesting that it is also Y-carboxylated like the 
native molecule. 
EXAMPLE 10. Purification of human protein C from the 
milk of transgenic animals 
(1) Preparation of whey samples 
Milk from several WAPpC1 transgenic mouse lines was 
pooled, chilled on ice, diluted 6-fold with 50 mM Tris-HCl, 
0.15M NaCl pH 7.2 (TBS) (1 ml milk per 5 ml TBS), and 
centrifuged at 125,000xg for 30 minutes at 4°C. Following 
centrifugation, the whey was collected and pooled using a 
pasteur pipet and pooled, being careful not to disturb the 
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fatty overlayer or the casein pellet. Samples were removed 
from the pool for later assay and then both the samples and 
the pooled whey were frozen and stored at -90° C. Human 
protein C in samples was determined by ELISA, as 
described above. 
Individual whey pools were thawed at 2 CC, combined, 
and the amount of human protein C (hPC) in the combined 
pool was determined by ELISA using the 7D7B10 mono 
clonal antibody (Mab). The combined pool contained 
approximately 30 ugh PC, determined by this assay, which 
was within 20% of the total determined by adding determi 
nations of the individual pools. 
The combined pool, approximately 150 ml, was dialyzed 
(14,000 MW cutoff) against 25 mM EDTA-TBS diluted 
5-fold with pure water. The dialyzed whey was concentrated 
5-fold by lyophilization and subsequent reconstitution with 
nanopure water, to yield a final buffer concentration equiva 
lent to 25 mM EDTA in TBS, and a 5-fold increase in protein 
concentration. The concentrated whey contained 930 mg 
protein, as estimated by optical absorption at 280 nm, at 16 
mg/ml. 
(2) Immunoaffinity chromatography 
The resin immunosorbent (AffiprepTM) used to purify 
human protein C in the whey of transgenic mice contained 
3.3 mg 7D7B10 Mab/ml of Afiprep resin. The 7d7B10 
Affiprep resin was assessed by mock immunopurification 
using 30 ug of plasma derived hPC doped into control 
(nontransgenic) mouse whey. Approximately the same rela 
tive amount of total protein was loaded onto the column (660 
mg on a 10 mL Affiprep) and otherwise processed as 
described below. 
Freshly concentrated whey (16 mg/ml, 930 mg total 
protein, as determined by optical absorption at 280 nm) was 
batch-loaded onto 13 ml of 7D7B10 Afiprep containing 3.3 
mg 7D7B10 Mab/ml resin for 4 hours at 2° C., without 
addition of carrier protein. The column was fresh and the 
high total (background) protein loading was thought to be 
enough to condition the column. The resin was then loaded 
into a 1 cm diameter column and washed with 25 mM 
EDTA-TBS until baseline optical density (O.D.) was 
detected at 280 nm (3 column volumes to obtain <0.0005 
O.D.) 
The column was then eluted with 25 mM CaCl in TBS 
pH 7.2, followed by 100 mM CaCl, in TBS, followed by 4M 
NaCl, followed by 2M Nathiocyanate at 0.5 ml/min. The 
column was re-equilibrated with 5 column volumes of 25 
mM EDTA-TBS, 0.02% sodium azide. 
All peak pools were dialyzed in a 100-fold dilution (by 
nanopure water) of 50 mM imidazole, 0.1M NaCl buffer 
using a 14,000 MW cutoff dialysis tubing, then lyophilized, 
then reconstituted to 50 mM imidazole, 0.1. NaCl buffer 
strength using nanopure water resulting in a 100-fold con 
centration of protein. 
Samples of these eluate pool concentrates were prepared 
as per the method of Laemmli (1970), applied to a 15 well, 
9 cmx2 cm, 4% stacking gel above a 7.5 cm, 7.5% resolving 
(30%: 2.7% bis) sodium dodecylsulphate polyacrylamide 
gel and electrophoresed (SDS-PAGE). After electrophoresis, 
the gel was stained with 1.25% Coomassie Blue dye solu 
tion. 
The area of the eluate peaks obtained from immunopuri 
fication of whey from WAPpC1-transgenic mice was found 
to be very similar to the mock trial using an equivalent 
amount of (plasma derived) hPC-doped whey from control 
mice. Assay of 100-fold concentrated 25 mM CaCl eluate 
product from WAPpCl transgenics showed 40% yield based 
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upon densitometry of SDS-PAGE stained with Coomassie 
Blue (yield not determined for mock purification). The total 
peak areas from mock- and WAPpCl-whey were approxi 
mately the same for all eluate peaks including the 2M Na 
thiocyanate peak. Approximately 2 ug of hPC antigen 
(ELISA with immunocapture using 7D7B10 Mab) was 
detected in the column fall through which had been com 
bined with EDTA-TBS wash. Approximately 14 ug of hPC 
was detected in the 25 mM Ca' eluate pool, less than 0.1 
ug hPC antigen in the 100 mM Ca' eluate pool, no hPC 
antigen was detected in the 4MNaCl pool, approximately 10 
pug of hPC was detected in the 2MNathiocynate eluate pool. 
Thus, 87% of the hPC antigen applied to the column was 
accounted for in the total antigen recovered from column 
effluents. A 47% antigen yield was obtained based upon the 
hPC antigen recovered in the 25 mM Ca' eluate peak. 
The starting whey applied to the column, the 2M sodium 
thiocyanate eluate, the 25 mM Ca' eluate product, and a 
reference hPC derived from plasma by the American Red 
Cross (Lot #28300277, supplied by Dr. Carolyn Orthner) 
were analyzed by SDS-PAGE, both reduced and non-re 
duced. The 2M sodium thiocynate and 25 mM Ca' eluate 
pools were concentrated as described above and 4 ug of 
antigen applied to the gel for each lane. The immunopurified 
hPC reference was applied to the gel as 4 ug total protein 
based upon O.D. at 280 nm. Scanning densitometry of this 
reference hPC indicated that the sample was greater than 
99% pure on nonreduced SDS-PAGE, and 71% pure on 
reduced SDS-PAGE. Subsequent antigen assays performed 
on the hPC reference material indicated the concentration of 
the sample to be such that only 2.7 g of the reference 
sample was applied to the gel. The 25 mM Ca' eluate 
product is greater than 94% pure based upon non-reduced 
SDS-PAGE and 86% pure based upon reduced SDS-PAGE. 
The staining intensity of the 25 mM Ca' eluate lanes is 
consistent with our previous experience for 4 ug antigen 
applications. The bands corresponding to reference hPC 
possessed lighter intensity relative to the 25 mM Ca” 
eluate. A slightly split band at approximately 62,000 relative 
molecular weight (Mr) is seen for both the non-reduced 
reference hPC and the 25 mM Ca" eluate. A doublet at 
about 40,000 Mr and a diffuse single band at 22,000 Mr is 
seen for both the reduced reference hPC and 25 mM Ca” 
eluate. The 22,000 Mr band appearing in the hPC reference 
is seen to be somewhat more diffuse or heterogeneous than 
the similar band appearing in the 25 mM Ca' eluate from 
the whey of transgenic mice. The sodium thiocyanate peak 
showed a band in excess of 180,000 Mr in the nonreduced 
sample and multiple bands at 50,000 Mr and 25,000 Mr in 
the reduced sample. 
The chromatography of the WAPpC1-whey was nearly 
identical to the mock run using plasma-derived hPC doped 
into control whey. The total areas and yields of hPC in the 
25 mM Ca” eluates and areas of 2M sodium thiocyanate 
peaks for both runs were similar and thus the binding 
characteristics of the 7D7B10 Mab onto transgenic hPC or 
plasma-derived hPC were similar. This is consistent with the 
similarity found between plasma-derived and transgenic 
hPC Ca”- dependent conformers as judged by ELISA 
assays using the 7D7B10 Mab to immunocapture from 
whey. The primary structure as judged by SDS-PAGE 
appears to be similar, with the amount of ot-form and 3-form 
heavy chain being essentially the same for plasma-derived 
and transgenic hPC; the transgenic having 68% o-form and 
32% B-form while the plasma-derived material possessed 
69% o-form and 31% B-form. The light chains were also 
similar in size for both reference and transgenic hPC. 
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Previous experience with SDS-PAGE using Coomassie Blue 
staining of hPC has shown linearity for both chains over the 
range of 2-5 ugh PC applied to the gel. Thus, much of the 
elements of post-translational, proteolytic processing 
appears to have occurred properly in the mammary tissue. 
The purity of these runs also demonstrates the satisfactory 
utility of the immunopurification procedure developed for 
the murine system. It is believed that the tight binding of the 
hPC antigen found by ELISA in the 2M thiocyanate peak of 
the whey from transgenic mice (assay not done for mock 
run) is typical of yields found for fresh immunosorbents and 
not due to an aberrant hPC structure. The total background 
protein did not seem to condition the column and thus the 
interaction is thought to be specific with the 7D7B10 Mab. 
Overall, this two step procedure results in a minimum 
purification factor of 27,000 for the hPC recovered from 
mouse milk. A large-scale purification process could employ 
a citrate or EDTA precipitation coupled with low speed 
centrifugation in place of the ultracentrifugation step used 
for mouse milk. 
Both amidolytic and anti-coagulant assays were per 
formed upon immunopurified milk from transgenic mice. 
Within the sensitivity of these assays, the amidolytic and 
anti-coagulant activity was the same as plasma-derived 
immunopurified protein C. For both types of assays, the 
specific activity was greater than 270 U/mg. 
What we claim is: 
1. A transgenic non-human mammal that contains and 
expresses a human protein C DNA construct in the cells of 
its mammary gland, wherein the DNA construct consists of: 
(a) a mammary gland promoter, 
(b) a nucleotide sequence that encodes a signal peptide, 
wherein said signal peptide is effective in directing the 
secretion of an associated polypeptide into the milk of 
said transgenic non-human mammal, and wherein said 
signal peptide-encoding nucleotide sequence is opera 
tively associated with said mammary gland promoter, 
and 
(c) a nucleotide sequence encoding human protein C that 
is operatively associated with said signal peptide-en 
coding nucleotide sequence, 
wherein human protein C is secreted into the milk of said 
transgenic non-human mammal, and when purified, 
said protein C has a specific activity more than about 
80% of the specific activity of human protein C isolated 
from human plasma, as determined by an assay of 
protein C serine protease activity or anticoagulant 
activity, and 
wherein said non-human mammal is selected from the 
group consisting of mouse, pig, sheep, goat and cattle. 
2. The transgenic non-human mammal of claim 1, 
wherein said promoter is selected from the group consisting 
of a whey acidic protein promoter, a casein promoter, a 
lactalbumin promoter and a f-lactoglobulin promoter. 
3. The transgenic non-human mammal of claim 2, 
wherein promoter is a whey acidic protein promoter or a f5-lactoglobulin promoter. 
4. The transgenic non-human mammal of claim 3, 
wherein said promoter is a whey acidic protein promoter. 
5. The transgenic non-human mammal of claim 1, 
wherein said human protein C isolated from said transgenic 
non-human mammal has a specific activity that is about 80% 
to about 100% of the specific activity of human protein C 
isolated from human plasma. 
6. The transgenic non-human mammal of claim 5, 
wherein said specific activity is determined by an activated 
partial thromboplastin clotting time assay. 
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7. The transgenic non-human mammal of claim 5, 
wherein said promoter is a whey acidic protein promoter or 
a B-lactoglobulin promoter. 
8. A process for the production of protein C, comprising 
18 
tively associated with said mammary gland promoter, 
and 
(c) a nucleotide sequence encoding human protein C that 
is operatively associated with said signal peptide-en 
the steps of: 5 coding nucleotide sequence, 
(a) providing a transgenic non-human mammal that con- wherein human protein C is secreted into the milk of said 
tains and expresses a human protein C DNA construct transgenic non-human mammal, and when purified, 
in the cells of its mammary gland, wherein the DNA said protein C has a specific activity more than about 
construct consists of: 80% of the specific activity of human protein C isolated 
(i) a mammary gland promoter, O from human plasma, as determined by an assay of 
(ii) a nucleotide sequence that encodes a signal peptide, protein C enne protease activity or anticoagulant 
wherein said signal peptide is effective in directing activity, an a 
the secretion of an associated polypeptide into the wherein said non-human mammal is selected from the 
milk of said transgenic non-human mammal, and group consisting of mouse, pig, sheep, goat and cattle. 
wherein said signal peptide-encoding nucleotide 15 16. The transgenic non-human mammal of claim 15, 
sequence is operatively associated with said mam 
mary gland promoter, and 
(iii) a nucleotide sequence encoding human protein C 
that is operatively associated with said signal pep 
tide-encoding nucleotide sequence, 
wherein human protein C is secreted into the milk of said 
transgenic non-human mammal, and when purified, 
said protein C has a specific activity more than about 
80% of the specific activity of human protein C isolated 
from human plasma, as determined by an assay of 
protein C serine protease activity or anticoagulant 
activity, and 
wherein said non-human mammal is selected from the 
group consisting of mouse, pig, sheep, goat and cattle, 
(b) producing milk from said transgenic non-human mam 
mal, 
(c) collecting said milk, and 
20 
25 
30 
wherein said human protein C isolated from said transgenic 
non-human mammal has a specific activity that is about 80% 
to about 100% of the specific activity of human protein C 
isolated from human plasma. 
17. The transgenic non-human mammal of claim 16, 
wherein said specific activity is determined by an activated 
partial thromboplastin clotting time assay. 
18. A process for the production of protein C, comprising 
the steps of: 
(a) providing a transgenic non-human mammal that con 
tains and expresses a human protein C DNA construct 
in the cells of its mammary gland, wherein the DNA 
construct consists of: 
(i) a mammary gland promoter selected from the group 
consisting of a whey acidic protein promoter, a 
casein promoter, alactalbumin promoter and a B-lac 
toglobulin promoter, 
(ii) a nucleotide sequence that encodes a signal peptide, 
wherein said signal peptide is effective in directing 
the secretion of an associated polypeptide into the 
milk of said transgenic non-human mammal, and 
wherein said signal peptide-encoding nucleotide 
sequence is operatively associated with said mam 
mary gland promoter, and 
(iii) a nucleotide sequence encoding human protein C 
that is operatively associated with said signal pep 
tide-encoding nucleotide sequence, 
wherein human protein C is secreted into the milk of said 
transgenic non-human mammal, and when purified, 
(d) isolating said protein C from said milk. 
9. The process of claim 8, wherein said promoter is 35 
selected from the group consisting of a whey acidic protein 
promoter, a casein promoter, a lactalbumin promoter and a 
B-lactoglobulin promoter. 
10. The process of claim 9, wherein promoter is a whey 
acidic protein promoter or a B-lactoglobulin promoter. 40 
11. The process of claim 10, wherein said promoter is a 
whey acidic protein promoter. 
12. The transgenic non-human mammal of claim 8, 
wherein said human protein C isolated from said transgenic 
non-human mammal has a specific activity that is about 80% 5 said protein C has a specific activity more than about 
to about 100% of the specific activity of human protein C 80% of the specific activity of human protein C isolated 
isolated from human plasma from human plasma, as determined by an assay of 
13. The transgenic non-human mammal of claim 12 protein C serine protease activity or anticoagulant 
wherein said specific activity is determined by an activated activity, and 
partial thromboplastin clotting time assay. 50 wherein said non-human mammal is selected from the 
14. The transgenic non-human mammal of claim 13, group consisting of mouse, pig, sheep, goat and cattle, 
wherein said promoter is a whey acidic protein promoter or (b) producing milk from said transgenic non-human mam 
a B-lactoglobulin promoter. mal, 
15. A transgenic non-human mammal that contains and (c) collecting said milk, and 
expresses a human protein C DNA construct in the cells of 55 d) isolati id protein C f id nilk. its mammary gland, wherein the DNA construct consists of: (d) isolating said protein C from said mi 19. The transgenic non-human mammal of claim 18, 
(a) a mammary gland promoter selected from the group wherein said human protein C isolated from said transgenic 
consisting of a whey acidic protein promoter, a casein non-human mammal has a specific activity that is about 80% 
promoter, alactalbumin promoter and a B-lactoglobulin to about 100% of the specific activity of human protein C 
promoter, isolated from human plasma. 
(b) a nucleotide sequence that encodes a signal peptide, 20. The transgenic non-human mammal of claim 19, 
wherein said signal peptide is effective in directing the wherein said specific activity is determined by an activated 
secretion of an associated polypeptide into the milk of partial thromboplastin clotting time assay. 
said transgenic non-human mammal, and wherein said 
signal peptide-encoding nucleotide Sequence is opera- ck : k k :: 
